Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade · PMID 42321916
View analysis →A grade · PMID 42372741
View analysis →A grade · PMID 42382416
View analysis →A grade · PMID 42150584
View analysis →This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 81.0/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 10.0; sample size: 90.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 81.0/100. Study design: 80.0; human relevance: 95.0; therapeutic relevance: 60.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 81.0/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 20.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 81.0/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 100.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 81.0/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 42.4; sample size: 70.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 80.9/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 52.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 80.8/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 44.2; sample size: 50.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 80.6/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 38.2; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 80.6/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 55.7; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 80.6/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 58.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 80.5/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 57.7; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 80.5/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 50.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 80.4/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 52.1; sample size: 30.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 80.3/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 54.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 80.3/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 64.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 80.2/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 66.2; sample size: 80.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 80.2/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 46.2; sample size: 40.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 80.2/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 71.1; sample size: 70.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 80.2/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 61.0; sample size: 60.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 80.2/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 56.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
